Dragonfly Therapeutics, Inc. announced an expansion of its strategic collaboration with Merck, known as MSD outside of the United States and Canada to discover, develop and commercialize a number of Dragonfly’s candidate natural killer (“NK”) cell engager immunotherapies for oncology, infectious disease and immune disorders.
